H3N2 News and Research

RSS

Influenza A virus subtype H3N2 (also H3N2) is a subtype of viruses that cause influenza (flu). H3N2 viruses can infect birds and mammals. In birds, humans, and pigs, the virus has mutated into many strains. H3N2 is increasingly abundant in seasonal influenza, which kills an estimated 36,000 people in the United States each year.

Lab results shows H1N1 virus does not change into virulent superbug

A laboratory study by University of Maryland researchers suggests that some of the worst fears about a virulent H1N1 pandemic flu season may not be realized this year, but does demonstrate the heightened communicability of the virus.

2 Sep 2009

Adamas Pharmaceuticals forges agreement with U.S. Naval Health Research Center for evaluating triple combination antiviral drug

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Naval Health Research Center for preclinical studies evaluating Adamas' triple combination antiviral drug (TCAD) therapy for influenza A, including novel influenza A/H1N1. TCAD therapy includes Adamas' investigational proprietary fixed-dose oral combination drug, to be administered adjunctively with a neuraminidase inhibitor, including Tamiflu (oseltamivir phosphate, Roche).

22 Aug 2009

H3N2 influenza unlikely to spread between humans

Seeing animals up close is an integral part of experiencing the state and county fairs that take place around the country each summer and fall. And with good hygiene, Kansas State University veterinary experts say fair visitors shouldn't worry about contracting diseases from animals.

11 Aug 2009

Iowa funds swine vaccine research

A grant from a state economic development fund will help Iowa State University researchers develop and evaluate a vaccine designed to protect swine from novel H1N1 and other strains of influenza.

5 Aug 2009

FDA approves vaccine for 2009-2010 flu season

The U.S. Food and Drug Administration today announced that it has approved a vaccine for 2009-2010 seasonal influenza in the United States.

20 Jul 2009

Scientists map sequence mutations of the 2009 H1N1 influenza A virus

In just two weeks from the time the first patient virus samples were made available, Singapore scientists report an evolutionary analysis of a critical protein produced by the 2009 H1N1 influenza A virus strain.

22 May 2009

Swine flu - All you need to know

Swine influenza or Swine flu is a respiratory disease commonly found in pigs which is caused by type A influenza virus - it causes high levels of illness in pigs but low death rates and while swine flu viruses may circulate among swine throughout the year, most outbreaks occur during the autumn and winter months similar to flu outbreaks in humans.

29 Apr 2009

Researchers look at how the host reacts to a flu virus infection

"Where there are many scientific works dealing solely with the flu virus, we have investigated how the host reacts to an infection," says Klaus Schughart, head of the Experimental Mouse Genetics research group.

29 Mar 2009

Brits battling to cope with 'killer' Australian flu strain

As doctors and hospitals in the UK struggle to deal with a flu epidemic, Brits are being warned that the current outbreak is expected to intensify in the new year as the potentially fatal Australian strain of influenza spreads across the country.

30 Dec 2008

Novavax announces positive results in trial of seasonal influenza VLP (trivalent) vaccine candidate

Novavax, Inc. has announced favorable results from a Phase IIa human clinical trial of its seasonal influenza VLP (trivalent) vaccine candidate.

12 Dec 2008

Vaxfectin-formulated H5N1 pandemic influenza achieves T-cell responses and cross-clade reactivity in humans

Vical Incorporated has announced that the company's Vaxfectin-formulated H5N1 pandemic influenza DNA vaccines induced T-cell responses against a matching strain of influenza virus and demonstrated cross-clade antibody responses against a different strain in a Phase 1 clinical trial.

11 Dec 2008

High dose flu vaccine boosts immune response in elderly

Giving people age 65 and older a dose four times larger than the standard flu vaccine boosts the amount of antibodies in their blood to levels considered protective against the flu, more so than the standard flu vaccine does. The findings from a study of nearly 4,000 people were presented Oct. 26 at a national meeting on infectious diseases.

26 Oct 2008

Southeast Asia the culprit in flu epidemics

According to the World Health Organisation (WHO) each year influenza epidemics are thought to infect between 5 and 15 per cent of the world's population.

17 Apr 2008

Molecular evolution of influenza A viruses circulated in Fujian Province, China

Fujian Center for Disease Control & Prevention, China, reported the molecular evolution of influenza A (H3N2) viruses in Fujian Province, south of China during the period 1996 to 2004 and demonstrated some key codons responsible for antigenic drift.

2 Apr 2008

Research helps explain why some flu strains cause major pandemics and others lead to seasonal epidemics

The exchange of genetic material between two closely related strains of the influenza A virus may have caused the 1947 and 1951 human flu epidemics, according to biologists.

6 Mar 2008

Seasonal flu levels trigger use of antiviral drugs

The Health Protection Agency has confirmed that the rate at which influenza viruses are now circulating in England has reached the point which triggers the use of antiviral drugs.

11 Jan 2008

Sanofi pasteur ships doses of Fluzone influenza vaccine for the 2007-2008 season

Sanofi pasteur, the vaccines division of the sanofi-aventis Group, has begun shipment of influenza vaccine (Fluzone, Influenza Virus Vaccine) in the United States for the 2007-2008 season.

13 Aug 2007

Tamiflu could halve the pandemic influenza death toll versus no intervention

Treatment with the oral antiviral Tamiflu (oseltamivir) and prophylaxis for people exposed to infected patients could be one of the most cost-effective strategies for reducing illness and death during an influenza pandemic.

23 Jun 2007

LigoCyte Pharmaceuticals presents data showing that immunization with their influenza H1N1-VLP formulation resulted in 100% protection from H1N1 and H3N2

LigoCyte Pharmaceuticals has presented preclinical data showing that immunization with their influenza virus-like particles (VLPs) induced heterosubtypic protection in a virus challenge study.

4 May 2007

Experimental flu vaccine produced using insect cells shows promise

An influenza vaccine produced with the use of insect cells appeared safe and produced an immunogenic response in healthy adults, suggesting promise as an alternative to using embryonated eggs for the development of influenza vaccine, according to a preliminary study in the April 11 issue of JAMA.

11 Apr 2007